Reading the tape
NASDAQ: ACLX
Arcellx, Inc.
Healthcare · Biotechnology
Market Cap
$6.73B
52w High
$115.13
52w Low
$47.86
P/E
-28.30
Volume
0.00
Outstanding Shares
58.51M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 77.82%Revenue (TTM): -79.35%FCF (TTM): -119.38%
What changed
The stock rose 77.82% over the last year. Revenue declined 79.35% over the trailing twelve months. Operating margin moved from -127.46% to -1,135.61%. Free cash flow declined 119.38% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -1,135.61%. A decisive move in revenue — currently down 79.35% — would be the clearest signal to resolve the ambiguity.
Company profile
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases.
CEORami Elghandour
SectorHealthcare
IndustryBiotechnology
Employees163
IPO dateFeb 4, 2022
Valuation
Forward P/E—
EV/EBITDA-18.62
Enterprise value$3.69B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth-89.17%
Gross margin-64.81%▼26.43%vs FY2024
Operating margin-1,135.61%▼790.98%vs FY2024
ROE-56.9%▼141.06%vs FY2024
Analyst consensus
RatingHold
Target price$112.45▼2.28%
7
Buy
11
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$1.13 · Revenue est $6.07M
View